Market observers note that Tempus AI stock forecast aligns with broader biotech AI momentum, with trading volumes spiking 12% in the last quarter, suggesting investor sentiment remains bullish amid rising demand for real-time clinical data analytics. Revenue Miss : Despite a 36% year-over-year revenue increase, the figure fell short of our projection by 2.7%. Private economic data is set to take on an even bigger role Technical charts behind the Tempus AI stock forecast show a breakout above the 200-day moving average last week, signaling possible sustained upward momentum if volume confirms trend.